Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | PDE2A | O00408 | 4/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991083 | 1.00 | PTPN5 (0.55) | PTPN5CES2CES1PDE2AACP3 | |
| SCHEMBL342466 | 1.00 | PTPN5 (0.55) | PTPN5CES2CES1PDE2AACP3 | |
| SCHEMBL2276065 | 0.94 | PTPN5 (0.64) | PTPN5CES2CES1PDE2AKIF11 | |
| SCHEMBL2276063 | 0.94 | PTPN5 (0.64) | PTPN5CES2CES1PDE2AKIF11 | |
| SCHEMBL2276059 | 0.94 | PTPN5 (0.64) | PTPN5CES2CES1PDE2AKIF11 | |
| SCHEMBL11125737 | 0.88 | PTPN5 (0.46) | PTPN5CES2CES1PDE2AAKR1C3 | |
| SCHEMBL28611305 | 0.85 | TRPV1 (0.49) | PTPN5CES2CES1PDE2A | |
| SCHEMBL30521586 | 0.84 | PTPN5 (0.53) | PTPN5CES2CES1PDE2AHSD11B1 | |
| SCHEMBL18290606 | 0.84 | PTPN5 (0.53) | PTPN5CES2CES1PDE2ANOS3 | |
| SCHEMBL9668161 | 0.82 | PDE2A (0.56) | PTPN5CES2CES1PDE2AACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3962602-B1 | ITACONIC ACID DERIVATIVES AND USES THEREOF IN TREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2025-06-25 | — | — | EP | disclosed |
| US-20240360067-A1 | DERIVATIVES OF ITACONIC ACID AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-10-31 | — | — | US | disclosed |
| US-20240335451-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| CN-113584090-B | Biological preparation method of chemokine CCR 5 antagonist AD101 chiral intermediate | 浙江工业大学 | 2024-07-19 | — | — | CN | disclosed |
| EP-4384271-A1 | DERIVATIVES OF ITACONIC ACID AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Sitryx Therapeutics Limited (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-4359390-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | Sitryx Therapeutics Limited (GB) | 2024-05-01 | — | — | EP | disclosed |
| US-20240010606-A1 | FUMARATE DERIVATIVES AND THEIR MEDICAL USE | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-11 | — | — | US | disclosed |
| US-20230399287-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-12-14 | — | — | US | disclosed |
| CN-116970580-A | Short-chain dehydrogenase mutant derived from Raffina and application of short-chain dehydrogenase mutant in catalyzing aryl ketone to prepare chiral alcohol | 浙江工业大学 | 2023-10-31 | — | — | CN | disclosed |
| EP-4237404-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-20180305362-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-25 | — | — | US | disclosed |
| EP-3362454-A1 | EP4 ANTAGONISTS | Eisai R&D Management Co., Ltd. (JP) | 2018-08-22 | — | — | EP | disclosed |
| EP-3350187-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066633-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017046117-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | ABBVIE INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20170073353-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20070244319-A1 | Metallocenyl P-N ligands, preparation thereof, and use for asymmetric catalysis | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305362-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | PTPN5 4154/4885CES2 2580/4885CES1 619/4885 |
| US-10316040-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | PTPN5 4154/4885CES2 2580/4885CES1 619/4885 |
| US-20240360067-A1 | DERIVATIVES OF ITACONIC ACID AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | NFKBIA, NFATC1, RORC | PTPN5 1940/4885CES2 4735/4885CES1 1665/4885 |
| US-20240335451-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | TNF, HLA-DRB1, GSTK1 | PTPN5 525/4885CES2 2097/4885CES1 1140/4885 |
| US-20230399287-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, HLA-DRB1 | PTPN5 2124/4885CES2 3187/4885CES1 570/4885 |
| US-20170073353-A1 | SUBSTITUTED ISOXAZOLOPYRIDAZINONES AND ISOTHIAZOLOPYRIDAZINONES AND METHODS OF USE | GABRB1, GABBR1, GABBR2 | PTPN5 894/4885CES2 1484/4885CES1 1354/4885 |
| US-20240010606-A1 | FUMARATE DERIVATIVES AND THEIR MEDICAL USE | FH, SUCNR1, ARG2 | PTPN5 3653/4885CES2 4024/4885CES1 877/4885 |
| US-20070244319-A1 | Metallocenyl P-N ligands, preparation thereof, and use for asymmetric catalysis | PNN, PNMT, CPNE4 | PTPN5 3069/4885CES2 3531/4885CES1 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.